137 related articles for article (PubMed ID: 6361231)
1. Neurotensin analogs [D-TYR11] and [D-PHE11]neurotensin resist degradation by brain peptidases in vitro and in vivo.
Checler F; Vincent JP; Kitabgi P
J Pharmacol Exp Ther; 1983 Dec; 227(3):743-8. PubMed ID: 6361231
[TBL] [Abstract][Full Text] [Related]
2. Degradation of neurotensin by rat brain synaptic membranes: involvement of a thermolysin-like metalloendopeptidase (enkephalinase), angiotensin-converting enzyme, and other unidentified peptidases.
Checler F; Vincent JP; Kitabgi P
J Neurochem; 1983 Aug; 41(2):375-84. PubMed ID: 6308159
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
[TBL] [Abstract][Full Text] [Related]
4. Differential neurobehavioral effects of neurotensin and structural analogues.
Jolicoeur FB; Barbeau A; Rioux F; Quirion R; St-Pierre S
Peptides; 1981; 2(2):171-5. PubMed ID: 7291042
[TBL] [Abstract][Full Text] [Related]
5. Stability of [D-Trp11]-neurotensin to rat brain peptidases.
McDermott JR; Gibson AM; Biggins JA
Neurosci Lett; 1986 Dec; 72(1):79-83. PubMed ID: 3543750
[TBL] [Abstract][Full Text] [Related]
6. In vivo inactivation of neurotensin in dog ileum: major involvement of endopeptidase 24-11.
Checler F; Kostolanska B; Fox JA
J Pharmacol Exp Ther; 1988 Mar; 244(3):1040-4. PubMed ID: 2855236
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes.
Checler F; Vincent JP; Kitabgi P
J Biol Chem; 1986 Aug; 261(24):11274-81. PubMed ID: 3525564
[TBL] [Abstract][Full Text] [Related]
8. Neuromedin N: high affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases.
Checler F; Vincent JP; Kitabgi P
Eur J Pharmacol; 1986 Jul; 126(3):239-44. PubMed ID: 3019713
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases.
Kitabgi P
Peptides; 2006 Oct; 27(10):2515-22. PubMed ID: 16904239
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of neurotensin by rat brain synaptic membranes. Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase.
Checler F; Emson PC; Vincent JP; Kitabgi P
J Neurochem; 1984 Nov; 43(5):1295-301. PubMed ID: 6387047
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat.
Rivest R; St-Pierre S; Jolicoeur FB
Neuropharmacology; 1991 Jan; 30(1):47-52. PubMed ID: 1904561
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin-metabolizing peptidases in rat fundus plasma membranes.
Checler F; Barelli H; Kwan CY; Kitabgi P; Vincent JP
J Neurochem; 1987 Aug; 49(2):507-12. PubMed ID: 3298547
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.
Norman C; Beckett SR; Spicer CH; Ashton D; Langlois X; Bennett GW
J Psychopharmacol; 2008 May; 22(3):300-7. PubMed ID: 18208905
[TBL] [Abstract][Full Text] [Related]
14. [Synthesis and study of cyclic and linear analogs of neurotensin].
Grinshteĭne IV; Myshliakova NV; Vegner RE; Vosekalna IA; Gaĭlite EA
Bioorg Khim; 1985 Dec; 11(12):1589-97. PubMed ID: 4084322
[TBL] [Abstract][Full Text] [Related]
15. Involvement of dopamine in the central effect of neurotensin on intestinal motility in rats.
Fargeas MJ; Fioramonti J; Bueno L
Peptides; 1990; 11(6):1169-73. PubMed ID: 2087439
[TBL] [Abstract][Full Text] [Related]
16. Acute administration of neuroleptics decreases neurotensin metabolism on intact, regional rat brain slices.
Konkoy CS; Waters SM; Davis TP
J Pharmacol Exp Ther; 1994 May; 269(2):555-63. PubMed ID: 7910209
[TBL] [Abstract][Full Text] [Related]
17. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies with neurotensin: analysis of positions 9, 10 and 11.
Quirion R; Regoli D; Rioux F; St-Pierre S
Br J Pharmacol; 1980 Aug; 69(4):689-92. PubMed ID: 7437646
[TBL] [Abstract][Full Text] [Related]
19. Neurotensin analogues. Structure--activity relationships.
Rivier JE; Lazarus LH; Perrin MH; Brown MR
J Med Chem; 1977 Nov; 20(11):1409-12. PubMed ID: 915901
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of neurotensin degradation by rat brain peptidases.
McDermott JR; Smith AI; Edwardson JA; Griffiths EC
Regul Pept; 1982 May; 3(5-6):397-404. PubMed ID: 7051196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
